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Abstract
Background: Emerging evidence suggests that statins may decrease the risk of cancers. However, available evidence on
prostate cancer (PCa) is conflicting. We therefore examined the association between statin use and risk of PCa by
conducting a detailed meta-analysis of all observational studies published regarding this subject.
Methods: Literature search in PubMed database was undertaken through February 2012 looking for observational studies
evaluating the association between statin use and risk of PCa. Before meta-analysis, the studies were evaluated for
publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated
using random-effects model (DerSimonian and Laird method). Subgroup analyses, sensitivity analysis and cumulative meta-
analysis were also performed.
Results: A total of 27 (15 cohort and 12 case-control) studies contributed to the analysis. There was heterogeneity among
the studies but no publication bias. Statin use significantly reduced the risk of both total PCa by 7% (RR 0.93, 95% CI 0.87–
0.99, p= 0.03) and clinically important advanced PCa by 20% (RR 0.80, 95% CI 0.70–0.90, p,0.001). Long-term statin use did
not significantly affect the risk of total PCa (RR 0.94, 95% CI 0.84–1.05, p = 0.31). Stratification by study design did not
substantially influence the RR. Furthermore, sensitivity analysis confirmed the stability of results. Cumulative meta-analysis
showed a change in trend of reporting risk from positive to negative in statin users between 1993 and 2011.
Conclusions: Our meta-analysis provides evidence supporting the hypothesis that statins reduce the risk of both total PCa
and clinically important advanced PCa. Further research is needed to confirm these findings and to identify the underlying
biological mechanisms.
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Introduction
Prostate cancer (PCa) is the sixth leading cause of cancer death
in males worldwide [1]. The developed countries carry most of the
disease burden, accounting for nearly three quarters (72%) of the
total in 2008 [2]. It is the second leading cause of cancer death in
American men, after lung cancer [3].
Statins (3-hydroxy-3-methyl glutaryl-coenzyme A reductase
inhibitors), a group of cholesterol lowering drugs, have shown
PCa growth inhibiting potential both in animal [4] and clinical
studies [5–7]. However, evidence on statins effect on overall PCa
risk has been more controversial, with some studies having not
identified any effect [8–10], others having described an increased
overall PCa risk [11–14], whilst remaining studies having reported
reduced overall risk [15–17]. Some randomized clinical trials
(RCTs) on statin use in coronary heart disease [18,19], report non-
significant decreased incidence of PCa among statin users
compared to non users, but most of the results were ambiguous
because of inadequate power. Currently there is only one on-going
clinical trial (simvastatin vs. placebo) which examines the biologic
effects of statins on prostate cancer in humans [20].
This issue was discussed in previously conducted meta-analyses’
[21–23] which have analyzed statins chemopreventative effect in
overall cancers and site-specific cancers. No significant association
was found between statin use and total PCa risk in these studies. A
recent meta-analysis done by Bonovas et al. [24], focussing on PCa
risk in statin users, included 6 RCTs and 13 observational studies
published between 1993 and 2007, and reported no association. In
contrast, they concluded that there was a negative association
between statin use and advanced PCa risk. However, 17 more
studies [5–7,25–38] evaluating the association between statins use
and risk of PCa were published after 2007. In the present meta-
analysis, we examined statin use in relation to total PCa and also




Two authors independently performed the literature search by
using PubMed Database up to February 2012. Search terms
include: ‘‘statin(s)’’ or ‘‘HMG-CoA reductase inhibitor(s)’’ or
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‘‘lipid-lowering agent(s)’’ or ‘‘atorvastatin’’ or ‘‘cerivastatin’’ or
‘‘fluvastatin’’ or ‘‘lovastatin’’ or ‘‘mevastatin’’ or ‘‘pravastatin’’ or
‘‘rivastatin’’ or ‘‘rosuvastatin’’ or ‘‘simvastatin’’ and ‘‘cancer(s)’’ or
‘‘neoplasm(s)’’ or ‘‘malignancy(ies)’’ with limits; Humans and
English. The titles and abstracts of the resulting articles were
examined to exclude irrelevant studies. The full texts of remaining
articles were read to extract information on the topic of interest.
Bibliographies and citation sections of retrieved articles were also
reviewed for additional pertinent studies.
Inclusion and exclusion criteria
The studies considered in this meta-analysis were all observa-
tional (cohort or case-control) studies that evaluated exposure to
statins and risk of PCa. Any discrepancies were addressed by a
joint re-evaluation of the original article. Articles were excluded if
they were reviews, letters to the editor without original data,
editorials and case reports. When there were multiple publications
from the same population, only data from the most recent report
were included in the meta-analysis and remaining were excluded
[39–42].
Data extraction
Two authors independently reviewed the primary studies to
assess the appropriateness for inclusion in the present meta-
analysis and data were extracted. The following information was
assayed from each study: (i) first author’s last name, year of
publication, and country of the population studied; (ii) study
design; (iii) number of male subjects and number of PCa cases; (iv)
relative risk (RR) estimates and 95% confidence intervals (CIs); (v)
definitions of statin exposure, long-term statin use and advanced
PCa; (vi) PCa assessment; and (vii) control for confounding factors
by matching or adjustments, if applicable. We extracted the RR
estimates that reflected the greatest degree of control for potential
confounders.
Quality assessment
The quality of each study was assessed independently by two
authors by using the Newcastle-Ottawa Scale (NOS) [43]. The
NOS consists of three parameters of quality: selection, compara-
bility, and outcome (cohort studies) or exposure (case-control
studies). The NOS assigns a maximum of four points for selection,
two points for comparability, and three points for exposure/
outcome. Therefore, nine points reflects the highest quality. Any
discrepancies were addressed by a joint revaluation of the original
article with a third author.
Data synthesis and analysis
Because the risk of PCa is low, the RR in prospective cohort
studies mathematically approximates the odds ratio [44], therefore
permitting the combination of cohort and case-control studies.
Publication bias was assessed using Begg and Mazumdar adjusted
rank correlation test and Egger regression asymmetry test [45,46].
To assess the heterogeneity among studies, we used the Cochran Q
and I2 statistics; for the Q statistic, a p value,0.10 was considered
statistically significant for heterogeneity; for I2, a value .50% is
considered a measure of heterogeneity [47]. The primary measure
was pooled RR of PCa from individual studies, calculated using
the random-effects model (DerSimonian and Laird method),
which accounts for heterogeneity among studies. Tests for
interaction using summery estimates were performed, using the
method described by Altman and Bland [48]. All analyses were
performed using STATA version 11.0 (StataCorp, College
Station, TX). All statistical tests were two-sided and p,0.05 was
considered statistically significant, except otherwise specified.
The primary outcome in this meta-analysis was reported as RR
with 95% CI of developing PCa in statin users. To assess any link
between (i) long-term statin use and total PCa, (ii) statin use and,
specifically, advanced PCa, we used the available data from studies
which reported RR estimates for these particular associations.
Subgroup analyses were performed according to (i) study design
(cohort and case-control), (ii) adjustment for prostate specific
antigen (PSA) testing (iii) adjustment for body mass index (BMI)
and/or adverse life style (ALS), and (iv) studies before and after
Bonovas et al., analysis [24], to examine the impact of these factors
on the association. To evaluate the stability of our results, we also
performed a one-way sensitivity analysis. The scope of this analysis
was to evaluate the influence of individual studies by estimating the
average RR in the absence of each study. Cumulative meta-
analysis was also performed to identify the change in trend of
reporting risk over time. The present work was performed as per
the guidelines proposed by the Meta-analysis of Observational
Studies in Epidemiology group [49] and Preferred Reporting




A total of 1,555,165 articles were identified during the initial
search (figure 1). After reviewing the titles and abstracts of these
articles, 1,555,120 were found to be ineligible as they were
reviews, editorials, case reports and others did not met the
inclusion criteria. After detailed evaluation of the remaining 45
full-text articles, 18 were excluded for reasons described in
figure 1.
Study characteristics
Twenty seven relevant studies were identified, including 15
cohort and 12 case-control studies involving a total of 1,893,571
male subjects including 56,847 PCa cases. Participants were
followed-up for 2 to 17 years and the studies have been published
between 1993 and 2011.
Fifteen cohort studies of statin use and risk of PCa were
published between 1993 and 2011 included 1,812,005 partici-
pants, followed-up for 2 to 17 years, reporting a total of 5,770
incident PCa cases among 518,278 statin users, whereas 10,375
incidents of PCa cases among 1,258,019 non-statin users. Five
studies reported a negative association between statin use and risk
of total PCa [5,6,25,26,28]. All studies assessed PCa diagnosis
through cancer registry, except for 3 [6,10,26] which assessed
diagnosis through medical records. Of the total fifteen cohort
studies, seven were conducted in United States (US)
[8,10,25,26,28,34,38], six in Europe [5,6,9,30,35,36], one in both
US and Europe [11], and one in Asia [13].
Twelve case-control studies have been published between 2000
and 2011. These studies included 81,566 participants, followed-up
for 3 to 13 years, reporting a total of 3,550 statin users among
31,862 PCa cases and 3,325 statin users among 40,872 controls.
Six studies reported a negative association between statin use and
risk of total PCa [7,15–17,27,29]. Statin use was ascertained by
review of medical records in 8 studies [7,12,14–17,29,32] and by
mailed questionnaires in 4 studies [27,31,33,37]. Of them, eight
studies were conducted in US [7,15,17,27,29,31,33,37], three in
Europe [12,14,16], and one in Asia [32].
All studies evaluated exposure specifically to statins and the risk
of PCa except for 2 studies [14,38] that examined the use of all
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cholesterol-lowering drugs like fibrates and bile acid-binding resins
along with statins. All studies were controlled for potential
confounding factors (at least for age) by matching or adjustment.
The characteristics of the selected studies are presented in table 1.
Further, 11 studies reported RR estimates on the association
between long-term statin use and risk of total PCa
[5,8,10,14,17,25,28,31,34,37,38] (table 2) and 7 studies presented
an examination of statin use in relation to advanced PCa
[5,8,10,14,25,37,38] (table 3).
Quality assessment results
With regard to cohort studies, all had an NOS score of 8. In the
case-control studies, 11 (92%) were of high quality (NOS score
.6), with an average NOS score of 7.7.
Main analysis
No publication bias was observed among studies using Begg’s p
value (p = 0.56), Egger’s (p = 0.12) test and the funnel plot, having
expected a funnel shape (figure 2). Because of significant
heterogeneity (pheterogeneity,0.001, I
2=82%), which was to be
expected due to some studies showing positive; no; or negative
association, a random-effects model was chosen over a fixed-effects
model. A pooled analysis of 27 studies found statin use to be
associated with significant reduction in the risk of total PCa (RR
0.93, 95% CI 0.87–0.99, p = 0.03). Both multivariable adjusted
RR estimates with 95% CIs of each study and pooled RR are
shown in figure 3.
Figure 1. Flowchart representing the selection process.
doi:10.1371/journal.pone.0046691.g001
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Subgroup analyses, sensitivity analysis and cumulative
meta-analysis
We found a significant inverse association between statin use
and risk of total PCa among cohort studies (RR 0.93, 95% CI
0.87–1.01, p = 0.09) but non-significant inverse association among
case-control studies (RR 0.87, 95% CI 0.72–1.05, p= 0.15)
(table 4). The pooled RR of the studies that were able to either
control for PSA levels by comprehensive PSA screening of the
entire population or adjusted for PSA testing was 0.91 (95% CI
0.81–1.02, p = 0.13) and for studies which did not adjust for PSA
testing the RR was 0.93 (95% CI 0.86–1.01, p = 0.10). Both
subgroups presented an inverse association between statin use and
PCa. Studies adjusted for BMI and/or ALS showed a significant
inverse association (RR 0.88, 95% CI 0.78–0.99, p= 0.04) but this
was not observed in studies not adjusted for either BMI and/or













use" Number of variables adjusted#
Lovastatin study groups, 1993 (U.S., Canada & Finland)
[11]{
NR 504 5 a A 1
Blais et al., 2000 (Canada) [15]1 6 (1988–1994) 858 78 b NR 1, 27, 31, 33, 34
Graaf et al., 2004 (Netherlands) [16]1 3 (1995–1998) 9,785 186 c NR 1, 3, 5, 11–13, 27, 29–31
Kaye and Jick, 2004 (U.K.) [12]1 12 (1990–2002) 8,020 569 d B 1, 4, 19, 32
Friis et al., 2005 (Denmark) [9]{ 13 (1989–2002) 168,133 1407 e C 1, 5, 28, 29
Shannon et al., 2005 (U.S.) [17]1 7 (1997–2004) 302 100 e C 1–5, 25, 27
Platz et al., 2006 (U.S.) [10]{ 12 (1990–2002) 34,989 2,579 d A 1, 3, 4, 8, 10, 19–26
Sato et al., 2006 (Japan) [13]{ 14 (1991–2005) 215 2 f A 1
Flick et al., 2007 (U.S.) [8]{ 2 (2002–2004) 69,047 888 g B 1–3
Murtola et al., 2007 (Finland) [14]1 7 (1995–2002) 49,446 24,723 g C 1, 11–17
Boudreau et al., 2008 (U.S.) [25]{ 2 (1990–2005) 83,372 2,532 g C 1, 3, 5, 7, 27
Friedman et al., 2008 (U.S.) [34]{ 9 (1994–2003) NR 1,706 e B 35
Smeeth et al., 2008 (U.K.) [35]{ 11 (1995–2006) 364,675 3,525 d B 1, 3, 9, 11–14, 27, 28, 35–38
Agalliu et al., 2008 (U.S.) [37]1 13 (2002–2005) 1,943 1,001 d A 1, 2, 4, 8, 19
Breau et al., 2010 (U.S.) [26]{ 17 (1990–2007) 2,447 224 d A 1, 3, 5, 9, 39–41
Haukka et al., 2010 (Finland) [30]{ 9 (1996–2005) 10,928 1051 d C 1, 42
Hippisley et al., 2010 (England & Wales) [36]{ 6 (2002–2008) 990,495 7,129 d B NR
Murtola et al., 2010 (Finland) [5]{ 8 (1996–2004) 23,208 1,594 d C 1, 8, 10, 12–17, 24, 35
Coogan et al., 2010 (U.S.) [31]1 6 (1992–2008) 3,374 1,367 e A 2, 4–6, 18, 19, 32, 43, 44
Loeb et al., 2010 (U.S.) [27]1 6 (2003–2009) 1,351 1,351 e B 45
Farwell et al., 2011 (England) [6]{ 10 (1997–2007) 55,875 546 h B 1, 3, 7–9, 18, 19, 39, 46–52
Tan et al., 2011 (Ohio) [28]{ 10 (2000–2010) 4,204 1,797 g B 1, 2, 4, 53, 54
Jacobs et al., 2011 (U.S.) [38]{ 10 (1997–2007) 3,913 NR i A 1–10, 18
Chang et al., 2011 (Taiwan) [32]1 3 (2005–2008) 1,940 388 g C 3, 5, 9, 27, 32, 39, 55, 56
Fowke et al., 2011 (U.S.) [33]1 8 (2002–2010) 2,148 1029 g A 1–4, 9, 8–10, 24, 45, 54, 55
Mondul et al., 2011 (Maryland) [29]1 13 (1993–2006) 2,399 683 d A 1, 2, 4, 10, 13, 19, 24
Marcella et al., 2011 (New Jersey) [7]1 3 (1997–2000) 767 387 g B 1, 2, 4, 6, 13, 57, 58
PCa, Prostate cancer; NR, Not reported.
*Publication year;
{Country of study conducted;
{Cohort studies;
1Case-control studies.
Ia, systematic use of lovastatin vs. SEER data; b, any use of statin vs. use of bile acid-binding resins; c, use of statins vs. no use of statins; d, current use of statins vs. no
current use of statins; e, any use of statins vs. no use of statins; f, systematic use of statins vs. general population; g, ever use of statins vs. no use of statins; h, use of
statins vs. use of anti-hypertensives; i, current use of cholesterol-lowering drugs vs. never use of cholesterol-lowering drugs.
"A, self-reported; B, medical records; C, prescription database.
#1, age; 2, race; 3, diabetes mellitus; 4, BMI; 5, NSAID use; 6, education; 7, elevated cholesterol; 8, history of PSA testing; 9, cardiovascular disease; 10, family history of
prostate cancer; 11, use of diuretics; 12, use of calcium channel blockers; 13, use of angiotensin-converting enzyme inhibitors; 14, use of angiotensin receptor blockers;
15, use of metformin; 16, use of sulfonylureas; 17, use of insulin; 18, alcohol use; 19, smoking; 20, height; 21, major ancestry; 22, vasectomy; 23, vigorous physical activity;
24, aspirin use; 25, total energy intake; 26, intakes of calcium, fructose, a-linolenic acid, tomato sauce, red meat, fish, supplemental zinc, and high intake of vitamin E; 27,
use of other lipid-lowering drugs; 28, use of cardiovascular drugs; 29, use of hormones; 30, prior hospitalisation; 31, chronic disease score; 32, frequency of physician
visits; 33, previous neoplasm; 34, use of fibric acids; 35, calendar period of PSA screening; 36, propensity score; 37, cancer; 38, dementia; 39, hypertension; 40, use of 5-a
reductase inhibitors; 41, use of a-blockers; 42, follow-up period; 43, study center; 44, interview year; 45, clinical stage and biopsy gleason score; 46, weight; 47, thyroid
disease; 48, renal failure; 49, chest pain; 50, mental illness; 51, lung disease; 52, gastro-intestinal disease; 53,number of cores taken; 54, prostate volume; 55, benign
prostatic hyperplasia; 56, matching variables.
doi:10.1371/journal.pone.0046691.t001
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ALS (RR 0.96, 95% CI 0.88–1.04, p = 0.35). A significant inverse
association with studies published after Bonovas et al. [24] (RR
0.91, 95% CI 0.84–0.99, p = 0.03) was observed as compared to
the studies published in the same time frame included in Bonovas
et al. (RR 0.95, 95% CI 0.82–1.11, p = 0.58). There was
heterogeneity among the studies in these subgroups but no
publication bias. Tests for interaction were found non-significant
for subgroups of different study design; adjustment for PSA;
adjustment for BMI and ALS; and time frame of Bonovas et al.
analysis (pinteraction=0.45, 0.76, 0.24 and 0.63, respectively).This
confirmed the robustness of the results.
To test the robustness of our findings, we also carried out a
sensitivity analysis. To do this, the overall effect size was calculated
by removing one study at a time. This analysis showed no
significant variation in pooled RR by excluding two outliers in
terms of very low sample size studies: e.g. the Lovastatin study
group [11] (RR 0.93, 95% CI 0.86–0.99); and the Sato et al.[13]
(RR 0.93, 95% CI 0.87–0.99). The same was identified by
excluding any of the other studies (RR lay between 0.92–0.96),
confirming the stability of present results.
A cumulative meta-analysis of total 27 studies was carried out to
evaluate the cumulative effect estimate over time. In 1993, the
Lovastatin study groups [11] reported a significant effect estimate
of 2.94 (95% CI 0.95–6.86). Between 1993 and 2005 5 studies
were published, with a cumulative RR being 0.85 (95% CI 0.53–
1.38). Between 2005 and 2011, 21 more publications were added
cumulatively, resulting in an overall effect estimate of 0.93 (95%
CI 0.87–0.99).
Results for long-term statin use
Long-term statin use (mostly $5 years of use) did not
significantly affect the risk of total PCa (RR 0.94, 95% CI 0.84–
1.05, p = 0.31). However, there was high evidence of heterogeneity
Table 2. Studies evaluating the association between long-term statin use and risk of total prostate cancer.
Study RR 95% CI Total prostate cancer cases
Definition of ‘‘long-term’’ statin
use{
Shannon et al., 2005 [17]{ 0.22 0.08–0.66 NR $2.85 years
Platz et al., 2006 [10]* 0.85 0.71–1.03 126 $5.0 years
Flick et al., 2007 [8]* 0.72 0.53–0.99 42 $5.0 years
Murtola et al., 2007 [14]{ 1.13 1.00–1.28 1043 $4 years
Boudreau et al., 2008 [25]* 1.06 0.83–1.34 1492 .5 years
Friedman et al., 2008 [34]* 1.04 0.93–1.17 NR .5 years
Agalliu et al., 2008 [37]{ 1.1 0.7–1.8 45 .10 years
Murtola et al., 2010 [5]* 0.70 0.45–1.08 53 $6.0 years
Coogan et al., 2010 [31]{ 1.4 0.8–2.5 NR .10 years
Tan et al., 2011 [28]* 0.72 0.53–0.94 42 .5 years
Jacobs et al., 2011 [38]* 1.02 0.93–1.12 859 $5.0 years
RR, Relative risk; CI, Confidence interval; NR, Not reported.
*Cohort studies;
{Case-control studies;
{Definition of long-term statin use was taken from original research articles.
doi:10.1371/journal.pone.0046691.t002
Table 3. Studies evaluating the association between statin use and risk of advanced prostate cancer.
Study RR 95% CI
Advanced PCa
cases Definition of ‘‘advanced PCa’’{
Platz et al., 2006 [10]* 0.51 0.30–0.86 316 Regionally invasive, metastatic, or fatal: stage T3b or worse, N1, M1, or
death from PC
Flick et al., 2007 [8]* 0.8 0.53–1.19 131 Surveillance, Epidemiology and End Results (SEER) staging system, stage
II–IV (regional) or VII (distant)
Murtola et al., 2007 [14]{ 0.75 0.62–0.91 3,700 Advanced PC; not further defined
Boudreau et al., 2008 [25]* 1.22 0.85–1.75 458 Advanced stage cancer defined as regional or distant stage
Agalliu et al., 2008 [37]{ 0.73 0.48–1.10 181 Advanced PC; not further defined
Murtola et al., 2010 [5]* 0.93 0.54–1.58 133 Men with stage T3N0/XM0/X, T4N0/XM0/X, T1-4N1M0 or T1-4N0-1M1
tumors combined
Jacobs et al., 2011 [38]* 0.81 0.61–1.08 317 American Joint Committee on cancer stage III or IV, or fatal PC of
unknown stage at diagnosis
RR, Relative risk; CI, Confidence interval; PCa, Prostate cancer.
*Cohort studies;
{Case-control studies;
{Definition of advanced prostate cancer was taken from original research articles.
doi:10.1371/journal.pone.0046691.t003
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among these studies (pheterogeneity = 0.001, I
2=65%) but no
publication bias [Begg’s (p = 0.28), Egger’s (p = 0.17)] (table 4).
Stratification by study design showed both a non-significant
inverse association among cohort studies (RR 0.91, 95% CI 0.81–
1.02, p = 0.12) and no association among case-control studies (RR
0.97, 95% CI 0.64–1.48, p = 0.92), with the pinteraction being
calculated at 0.74. The multivariable adjusted RR estimates with
95% CIs of each study and pooled RR are shown in figure 4.
Results for advanced PCa
Because of lack of observed heterogeneity among the studies
(pheterogeneity =0.13, I
2=38%), a fixed-effects model was chosen
over a random-effects model for this analysis. A statistically
significant inverse association between statin use and the risk of
advanced PCa (RR 0.80, 95% CI 0.70–0.90, p,0.001) was
identified. No publication bias was observed among these studies
[Begg’s (p = 0.90), Egger’s (p = 0.54)] (table 4). Stratification by
study design showed that statistically significant inverse association
existed among both the cohort (RR 0.85, 95% CI 0.72–1.00,
p = 0.04), and the case-control studies (RR 0.74, 95% CI 0.62–
0.88, p= 0.001) with the pinteraction being 0.25. The multivariable
adjusted RR estimates with 95% CIs of each study and pooled RR
are shown in figure 5.
Discussion
In the past decade, the role of statins in the development of PCa
has been increasingly understood. With the present updated
pooled analysis of 27 observational studies, a 7% reduction in total
PCa risk among statin users as compared to non-users was
observed and this association remained stable even after the
sensitivity analysis.
Present findings regarding total PCa relative risk reduction with
statins is at odds with both the Bonovas et al. [24] findings and,
previous meta-analyses’ [21–23]. This inconsistency is likely to be
associated with the inclusion of 8 new studies published after 2007
that showed a negative association between statin use and risk of
total PCa [5–7,25–29]. This trend towards significant inverse
association from 2007 onwards (publications after Bonovas et al.
[24] meta-analysis) is clearly demonstrated in the cumulative
analysis.
The decreased risk of total PCa in long-term statin users was
found here to be non-significant. This is likely to be associated with
varying patterns of statin use in different study populations. In
many cases, drug use can be irregular, with months of non-use
between periods of use [5,14]. Hence, cumulative amount of statin
defined daily doses (DDDs) could be small despite its long
duration. Conversely, other studies took into account the use of
statins at high doses, which resulted in high cumulative amount of
DDDs. From this point of view, it should be noted that the
decreasing trend in PCa relative risk has been found to be stronger
for cumulative amount of statin use than for duration of its use [5].
Also, the varying definition of ‘‘long-term use’’ could have led to
non-significant results. Moreover, the data on long-term use is
sparse (only 11 studies with 273,798 participants including 3,702
PCa cases) and divergent (9 out of 11 included studies had shown
positive or neutral association), thus neutralizing the effect of
statins on PCa risk reduction.
On the other hand, analysis of those reports which specifically
examined statin use in relation to the more clinically advanced
PCa (n=7) suggested a significant inverse association between
them. Although, the staging schemes were likely to be somewhat
different, with some studies considering Gleason grade only, whilst
others considered both the PCa grade and its stage, most of the
studies had considered regionally invasive/metastatic stage III–IV
cancer as advanced PCa.
In the subgroup analyses, stratification by study design did not
substantially affect the result. Analysis of the subgroup of studies
published after Bonovas et al., [24] showed significant inverse
association while the pooled estimate of the studies covered in
Bonovas et al. analysis could not demonstrate significant inverse
association. This trend of results becomes more discernible with
Figure 2. Assessment of publication bias. Funnel plot (publication bias assessment plot) of the relative risk of developing prostate cancer, by the
standard error, for all studies. Circles- studies included in the meta-analysis. Relative risks are displayed on a logarithmic scale. p = 0.56 for the Begg’s
test, and p= 0.12 for the Egger’s test.
doi:10.1371/journal.pone.0046691.g002
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the cumulative meta-analysis showing a change in reporting risk of
total PCa from positive in Lovastatin study group [11] to neutral
with combined analysis of six studies and then significant inverse
association with combined analysis of total 27 studies. This change
in the reported association could not be fully explained. The
plausible explanation is that low cholesterol might increase cancer
risk. This concern has persisted until the early 1990’s and it has
almost entirely disappeared in the post-statin era [50].
The change can also be because of the change in the screening
behavior of the population with regards to PSA testing. FDA has
approved serum PSA as a prostate cancer biomarker in 1994,
forever changing the diagnostic landscape in the field. With PSA
testing, men generally present clinically with early stage disease.
Thus, cancer populations considered in studies published prior to
1994 include many more advanced cancers than studies published
in the last 10 years. This also suggests that cholesterol levels in the
pre-PSA era have a greater chance of being a product of tumor
metabolism, leading to a positive; statin use (low cholesterol) -
cancer association, whereas cholesterol measures in post-PSA
studies are more likely to reflect the cholesterol environment prior
to the development of cancer. This would lead to a positive
correlation between high cholesterol and prostate cancer risk.
Thus, statins showed chemopreventive effect by reducing choles-
terol in these patients [50].
There may be a range of different mechanisms behind the
apparent reduction of PCa risk in statin users. Specifically, statins
inhibit inflammation, angiogenesis, cell proliferation, migration/
adhesion, invasion whilst promoting apoptosis, exhibiting selectiv-
ity for tumor cells over normal cells [51]. Statins lower the
concentration of mevalonate by inhibiting HMG-CoA reductase
and thus declining the isoprenylated intermediates that are known
to affect signalling pathways along the spectrum from cancer
Figure 3. Statin use and risk of prostate cancer. Pooled estimate of relative risk (RR) and 95% confidence intervals (CIs) of total prostate cancer
(PCa) associated with statin use based on 27 [in figure study by Sato et al. [13] is excluded due to its large CI (RR 4.56, 95% CI 0.06–25.39) and no
effect on the final pooled estimated RR] studies (15 cohort and 12 case-control studies) involving more than 1.8 million participants including 56,847
PCa cases. Squares indicate RR in each study. The square size is proportional to the weight of the corresponding study in the meta-analysis; the
length of horizontal lines represents the 95% CI. The unshaded diamond indicates the pooled RR and 95% CI (random-effects model).
doi:10.1371/journal.pone.0046691.g003
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formation to progression [52]. Furthermore, the observed
decreased relative risk of PCa among statin users is supported by
in-vitro studies [4,53,54], which report growth inhibition in
prostate-derived cell lines whilst in presence clinically relevant
drug concentrations. Apart from the anti-inflammatory and
immunomodulatory actions of statins, cholesterol lowering as well
as statin pleiotropy through inhibition of the synthesis of
isoprenoids has both been implicated in their anticancer properties
[55].
The major potential confounding variables in detecting PCa are
given by PSA level, BMI and lifestyle factors. Statin use has been
shown to affect PSA levels. Recently, a large longitudinal study
observed a decline of 4.1% in the median PSA level after initiating
a statin [56]. The potential biases introduced by statin influence on
PSA and health-seeking behaviour of statin users may be at play
but work in opposite directions. Statins lower PSA levels and
therefore delay the detection of cancer. Even a small decrease in
PSA levels at the population level could translate to lower
detection of PCa with an apparent inverse association between
cancer risk and statin use. This would lead to a lower risk of total
PCa. However, all the diagnosed PCa will progress to advanced
disease thus an increased risk of advanced PCa in statin users. On
the other hand, statin users are more likely to get PSA testing done
[10] and this can be associated with an earlier detection of PCa
leading to an increased risk of overall PCa, but a decreased risk of
advanced PCa. Lower detection of PCa, among statin users due to
decrease in PSA levels (detection bias) can mask the possible
protective effect of statins on overall PCa due to a differential use
of screening is important for distinguishing the effect of statins
from that of screening. An additional subgroup analyses of studies
that were able to control for PSA levels by comprehensive PSA
screening of the entire population or which adjusted for PSA
testing (n=6) [5,10,28,33,37,38] was performed. Statin’ use
remained associated with a reduced overall risk of PCa in both
the subgroup of studies, either adjusting or not adjusting for PSA
testing.
The possible confounding effect arising due to the indications
for which statins are prescribed also needs to be emphasized.
Statin users are more likely to be obese or present with ALS
behaviour as compared to non-users. This could also affect PCa
development or progression. The subgroup analyses of 11
[6,7,10,12,17,28,29,31,33,37,38] studies which adjusted for BMI
and/or ALS revealed a more robust inverse association as
compared to those studies which did not adjust for these factors.
Obesity and ALS habits such as alcohol, smoking etc. are well
known risk factors for the development of PCa [57].
The strength of the present analysis lies in inclusion of 27
observational studies reporting data of more than 1.8 million
participants, including 56,847 PCa cases. Our meta-analysis has
several limitations. First, we did not search for unpublished studies
for original data. Secondly, the included studies were different in
terms of study design, confounder adjustments and definitions of
Table 4. Overall effect estimates for prostate cancer and statin use according to study characteristics.
No. of
studies Pooled estimate Tests of heterogeneity pinteraction
Tests of publication
bias
RR (95% CI) p-value Q value (d.f.) p-value I2 (%) Begg’s p
Egger’s
p
All studies 27 0.93 (0.87–0.99) 0.03{ 145.30 (26) ,0.001 82 0.56I 0.12
Study design 0.451
Cohort 15 0.93 (0.87–1.01) 0.09{ 88.60 (14) ,0.001 84 0.56I 0.07
Case-control 12 0.87 (0.72–1.05) 0.15 56.64 (11) ,0.001 81 0.31I 0.09
PSA testing 0.761
Adjusted 6 0.91 (0.81–1.02) 0.13 14.87 (5) 0.011 66 .0.99I 0.49
Not adjusted 21 0.93 (0.86–1.01) 0.11 121.23 (20) ,0.001 83 0.53I 0.04
BMI and ALS 0.241
Adjusted 11 0.88 (0.78–0.99) 0.04{ 44.23 (10) ,0.001 77 0.54I 0.22
Not adjusted 16 0.96 (0.88–1.04) 0.37 81.09 (15) ,0.001 81 0.56I 0.12
Bonovas et al. [24] analysis 0.631
Before 10 0.95 (0.82–1.11) 0.58 26.62 (9) 0.002 66 0.73I 0.51
After 17 0.91 (0.84–0.99) 0.03{ 118.62 (16) ,0.001 87 0.27I 0.01
Results for long-term statin use 11 0.94 (0.84–1.05) 0.31 28.80 (10) 0.001 65 0.741 0.28I 0.17
Cohort studies 7 0.91 (0.81–1.02) 0.12 14.79 (6) 0.02 59 0.14I 0.02
Case-control studies 4 0.97 (0.64–1.48) 0.92 9.75 (3) 0.02 69 0.33I 0.49
Results for advanced prostate cancer 7 0.80 (0.70–0.90)* ,0.001{ 8.98 (6) 0.17{ 33 0.251 0.77I 0.90
Cohort studies 5 0.85 (0.72–1.00)* 0.04{ 7.75 (4) 0.10{ 48 0.81I 0.62
Case-control studies 2 0.74 (0.62–0.88)* 0.001{ 0.01 (1) 0.90{ - - -
PSA, Prostate specific antigen; BMI, Body mass index; ALS, Adverse life style; RR, Relative risk; CI, Confidence interval; d.f., Degree of freedom.
*Relative risk from fixed-effects model due to no heterogeneity among the studies;
{P value representing significant inverse association between statin use and prostate cancer;
{Statistically significant for homogeneity;
1Test of interaction was not statistically significant;
IStatistically significant for no publication bias.
doi:10.1371/journal.pone.0046691.t004
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drug exposure; long-term statin use; and advanced PCa. The lack
of data regarding exposure to PSA testing identified in 21 out of 27
studies included in the present analysis is the most important
weakness of the included studies, since PSA testing significantly
affects PCa detection [41]. Another, limitation is that only 11
studies have adjusted for potential risk factors like BMI and ALS.
Finally, our analysis was restricted to articles in the English
language, which may have somewhat biased the results.
In summary, our results suggest a decreased relative risk of PCa
in statin users as identified by a combined meta-analysis of 27
observational studies. The results support the hypothesis that
cholesterol-lowering with statins is beneficial for both PCa
Figure 4. Long-term statin use and risk of prostate cancer. Pooled estimate of relative risk (RR) and 95% confidence intervals (CIs) of total
prostate cancer (PCa) associated with long-term statin use based on 11 studies (7 cohort and 4 case-control studies) involving 273,798 participants
including 3,702 PCa cases. Squares indicate RR in each study. The square size is proportional to the weight of the corresponding study in the meta-
analysis; the length of horizontal lines represents the 95% CI. The unshaded diamond indicates the pooled RR and 95% CI (random-effects model).
doi:10.1371/journal.pone.0046691.g004
Figure 5. Statin use and risk of advanced prostate cancer. Pooled estimate of relative risk (RR) and 95% confidence intervals (CIs) of advanced
prostate cancer (PCa) associated with statin use based on 7 studies (5 cohort and 2 case-control studies) involving 266,209 participants including
5,236 advanced PCa cases. Squares indicate RR in each study. The square size is proportional to the weight of the corresponding study in the meta-
analysis; the length of horizontal lines represents the 95% CI. The unshaded diamond indicates the pooled RR and 95% CI (fixed-effects model).
doi:10.1371/journal.pone.0046691.g005
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prevention and for clinically important advanced PCa. Further
research is needed to address the role of PSA screening and
underlying biological mechanisms for this association to confirm
the putative protective effects of statins.
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